Literature DB >> 28455789

Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.

Jonathan M Eby1, Hazem Abdelkarim2, Lauren J Albee1, Abhishek Tripathi1, Xianlong Gao1, Brian F Volkman3, Vadim Gaponenko2, Matthias Majetschak4,5.   

Abstract

Chemokine (C-X-C motif) receptor 4 (CXCR4) regulates cell trafficking and plays important roles in the immune system. Ubiquitin has recently been identified as an endogenous non-cognate agonist of CXCR4, which activates CXCR4 via interaction sites that are distinct from those of the cognate agonist C-X-C motif chemokine ligand 12 (CXCL12). As compared with CXCL12, chemotactic activities of ubiquitin in primary human cells are poorly characterized. Furthermore, evidence for functional selectivity of CXCR4 agonists is lacking, and structural consequences of ubiquitin binding to CXCR4 are unknown. Here, we show that ubiquitin and CXCL12 have comparable chemotactic activities in normal human peripheral blood mononuclear cells, monocytes, vascular smooth muscle, and endothelial cells. Chemotactic activities of the CXCR4 ligands could be inhibited with the selective CXCR4 antagonist AMD3100 and with a peptide analogue of the second transmembrane domain of CXCR4. In human monocytes, ubiquitin- and CXCL12-induced chemotaxis could be inhibited with pertussis toxin and with inhibitors of phospholipase C, phosphatidylinositol 3 kinase, and extracellular signal-regulated kinase 1/2. Both agonists induced inositol trisphosphate production in vascular smooth muscle cells, which could be inhibited with AMD3100. In β-arrestin recruitment assays, ubiquitin did not sufficiently recruit β-arrestin2 to CXCR4 (EC50 > 10 μM), whereas the EC50 for CXCL12 was 4.6 nM (95% confidence interval 3.1-6.1 nM). Both agonists induced similar chemical shift changes in the 13C-1H-heteronuclear single quantum correlation (HSQC) spectrum of CXCR4 in membranes, whereas CXCL11 did not significantly alter the 13C-1H-HSQC spectrum of CXCR4. Our findings point towards ubiquitin as a biased agonist of CXCR4.

Entities:  

Keywords:  Biased agonist; CXCL12; Chemotaxis; Nuclear magnetic resonance spectroscopy; Stromal cell-derived factor-1α; Ubiquitin

Mesh:

Substances:

Year:  2017        PMID: 28455789      PMCID: PMC5660673          DOI: 10.1007/s11010-017-3044-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  Structural insights into substrate binding by the molecular chaperone DnaK.

Authors:  M Pellecchia; D L Montgomery; S Y Stevens; C W Vander Kooi; H P Feng; L M Gierasch; E R Zuiderweg
Journal:  Nat Struct Biol       Date:  2000-04

Review 2.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 3.  Using chemical shift perturbation to characterise ligand binding.

Authors:  Mike P Williamson
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2013-03-21       Impact factor: 9.795

4.  Serum ubiquitin via CXC chemokine receptor 4 triggered cyclooxygenase-1 ubiquitination possibly involved in the pathogenesis of aspirin resistance.

Authors:  Chunjiang Tan; Xiao Lu; Wenlie Chen; Songming Chen
Journal:  Clin Hemorheol Microcirc       Date:  2015       Impact factor: 2.375

5.  An ubiquitin-binding molecule can work as an inhibitor of ubiquitin processing enzymes and ubiquitin receptors.

Authors:  Thanh Nguyen; Minh Ho; Ambarnil Ghosh; Truc Kim; Sun Il Yun; Seung Seo Lee; Kyeong Kyu Kim
Journal:  Biochem Biophys Res Commun       Date:  2016-09-07       Impact factor: 3.575

6.  Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions.

Authors:  N I Tarasova; W G Rice; C J Michejda
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

7.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

8.  Extracellular ubiquitin increases expression of angiogenic molecules and stimulates angiogenesis in cardiac microvascular endothelial cells.

Authors:  Rebecca J Steagall; Christopher R Daniels; Suman Dalal; William L Joyner; Mahipal Singh; Krishna Singh
Journal:  Microcirculation       Date:  2014-05       Impact factor: 2.628

9.  Targeted delivery of ubiquitin-conjugated BH3 peptide-based Mcl-1 inhibitors into cancer cells.

Authors:  Avinash Muppidi; Kenichiro Doi; Selvakumar Edwardraja; Surya V S R K Pulavarti; Thomas Szyperski; Hong-Gang Wang; Qing Lin
Journal:  Bioconjug Chem       Date:  2014-01-22       Impact factor: 4.774

10.  New Insights into Mechanisms and Functions of Chemokine (C-X-C Motif) Receptor 4 Heteromerization in Vascular Smooth Muscle.

Authors:  Ann E Evans; Abhishek Tripathi; Heather M LaPorte; Lioubov I Brueggemann; Abhay Kumar Singh; Lauren J Albee; Kenneth L Byron; Nadya I Tarasova; Brian F Volkman; Thomas Yoonsang Cho; Vadim Gaponenko; Matthias Majetschak
Journal:  Int J Mol Sci       Date:  2016-06-20       Impact factor: 5.923

View more
  10 in total

1.  Regulation of the thrombin/protease-activated receptor 1 axis by chemokine (CXC motif) receptor 4.

Authors:  Xianlong Gao; You-Hong Cheng; Garrett A Enten; Anthony J DeSantis; Vadim Gaponenko; Matthias Majetschak
Journal:  J Biol Chem       Date:  2020-08-24       Impact factor: 5.157

2.  Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers.

Authors:  Khuraijam Dhanachandra Singh; Zaira P Jara; Terri Harford; Prasenjit Prasad Saha; Triveni R Pardhi; Russell Desnoyer; Sadashiva S Karnik
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-17       Impact factor: 11.205

3.  Class A G protein-coupled receptors assemble into functional higher-order hetero-oligomers.

Authors:  Xianlong Gao; Garrett A Enten; Anthony J DeSantis; Matthias Majetschak
Journal:  FEBS Lett       Date:  2021-06-11       Impact factor: 3.864

4.  Asymmetrical ligand-induced cross-regulation of chemokine (C-X-C motif) receptor 4 by α1-adrenergic receptors at the heteromeric receptor complex.

Authors:  Xianlong Gao; Lauren J Albee; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

5.  Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function.

Authors:  You-Hong Cheng; Jonathan M Eby; Heather M LaPorte; Brian F Volkman; Matthias Majetschak
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

Review 6.  Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.

Authors:  Erik De Clercq
Journal:  Antivir Chem Chemother       Date:  2019 Jan-Dec

7.  Natural and engineered chemokine (C-X-C motif) receptor 4 agonists prevent acute respiratory distress syndrome after lung ischemia-reperfusion injury and hemorrhage.

Authors:  Favin S Babu; Xiaomei Liang; Garrett A Enten; Anthony J DeSantis; Brian F Volkman; Xianlong Gao; Matthias Majetschak
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

8.  Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle.

Authors:  Lauren J Albee; Heather M LaPorte; Xianlong Gao; Jonathan M Eby; You-Hong Cheng; Amanda M Nevins; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak
Journal:  Open Biol       Date:  2018-01       Impact factor: 6.411

9.  Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFRmut NSCLC in diagnosis, follow-up and treatment.

Authors:  Florian Lüke; Raquel Blazquez; Rezan Fahrioglu Yamaci; Xin Lu; Benedikt Pregler; Stefan Hannus; Karin Menhart; Dirk Hellwig; Hans-Jürgen Wester; Saskia Kropf; Daniel Heudobler; Jirka Grosse; Jutta Moosbauer; Markus Hutterer; Peter Hau; Markus J Riemenschneider; Michaela Bayerlová; Annalen Bleckmann; Bernhard Polzer; Tim Beißbarth; Christoph A Klein; Tobias Pukrop
Journal:  Oncotarget       Date:  2018-04-10

10.  Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3.

Authors:  Xianlong Gao; Hazem Abdelkarim; Lauren J Albee; Brian F Volkman; Vadim Gaponenko; Matthias Majetschak
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.